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Experimental procedures
Instrumentation. Ultrafiltration of the nanoparticles was carried out using a 75 ml Amicon  Ultrafiltration Cell, Millipore  using a cellulose membrane with a cut-off of 10,000 Da.
UV-Vis absorption spectra were measured in water on a Perkin-Elmer Lambda 45 UV-Vis spectrophotometer with 1 cm path length quartz cuvettes.
Fluorescence spectra were measured in water on a Perkin-Elmer LS-50B fluorimeter with 1 cm path length quartz cuvettes. Infrared spectra were recorded on a Nicolet 5700 FT-IR instrument.
NMR spectra in the solution state were recorded on a Bruker Avance (250 MHz The hydrodynamic particle size (Dynamic Light Scattering, DLS) and Z-potential were measured with a Malvern Zetasizer Nano-S equipped with a HeNe laser (633nm) and a Peltier thermostatic system. Measurements were performed at 25 °C in water or PBS buffer at pH 7.0.
Transmission electron microscopy (TEM) was recorded on a Jeol 300PX instrument. One drop of sample was placed on the sample grid and the solvent was allowed to evaporate. In a sealed tube, 50 mg (0.08 mmol) of 5-(4-aminophenyl)-10,15,20-triphenylporphyrin and 198 L (0.8 mmol) of 3-(trimethoxysilyl)propyl isocyanate are dissolved in 6 mL of dry acetonitrile and the reaction mixture is heated at 90°C for 24 hours. The reaction is followed by TLC (eluent:
Petroleum Ether/EtOAc = 2:1, Rf = 0.22). The solvent is removed and the solid obtained is redissolved in 2 mL of CH 2 Cl 2 and precipitated in 60 mL of n-hexane. The product is recovered by centrifugation at 4,000 g for 20 minutes. The procedure is repeated 3 times providing after drying 52 mg of a violet powder (yield 74%). In a small conical vial, 17 mg (0.025 mmol) of mTHPC, 15.4 L (0.062 mmol) of 3-(trimethoxysilyl)propyl isocyanate and 8.6 L (0.062 mmol) of triethylamine are dissolved in 100 L of dry THF. The reaction is followed by TLC (eluent EtPet: iPrOH = 3:1, Rf mTHPC-Si = 0.3, Rf mTHPC-2Si = 0.4, Rf mTHPC-3Si = 0.5). The solvent is evaporated and the product is used without other purifications. In a small conical vial, 17 mg (0.025 mmol) of mTHPC, 24.7 L (0.1 mmol) of 3-(trimethoxysilyl)propyl isocyanate and 13.8 L (0.1 mmol) of triethylamine are dissolved in 100 L of dry THF. The reaction is followed by TLC (eluent EtPet: iPrOH = 3:1, Rf mTHPC-3Si = 0.5, Rf mTHPC-4Si = 0.6). The solvent is evaporated and the product is used without other purifications. 3. Synthesis and purification of the nanoparticles.
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Stober nanoparticles
To a thermostated vessel charged with 3 (4 mg, 0.005 mmol) and ethanol (20 mL), 100 L (0.45 mmol) of TEOS were added under stirring at 25 °C. Subsequently, 1 mL of a 14.8 M aqueous solution of ammonia was added to initiate the polymerization. After 16 hours, the solution was diluted to 80 mL with ethanol and concentrated to the original volume by ultrafiltration (Amicon stirred cell) through a regenerated cellulose membrane (cut-off 10 kDa) under nitrogen pressure (4 bar). The procedure was repeated five times with ethanol and 7 times with Milli-Q water. The resulting solution was filtered through a 0.22 m cellulose acetate membrane.
VTES nanoparticles (OS)
Brij 35 (90 mg, 75 mol, 15 mM) was dissolved under stirring in 5 ml of water at 25°C into a thermostated reaction vessel. Subsequently, 150 L (1.64 mol) of n-butanol, 25 L (10 mM DMSO solution) of 3 and VTES (45 mg, 0.24 mmol) were added. The mixture was vigorously stirred for 30 min (very important) and then 10 L of a 14.8 M aqueous solution of ammonia were added to initiate the polymerization. After 2 hours, the solution was transferred into an Amicon stirred cell and extensively ultrafiltrated with 1.5 L of Milli-Q water, using a regenerated cellulose membrane (cut-off size 10 kD). The nanoparticles suspension was then collected and filtered through a 0.22 m cellulose acetate filter.
PEGylated VTES nanoparticles (OS/PEG)
The appropriate amount of Brij 35 (see the following The mixture was vigorously stirred for 30 min (very important) and then 10 L of a 14.8 M aqueous solution of ammonia were added. The mixture was further stirred for 2 hours at constant temperature. Then 14.3 mg of Bio-Beads  SM per mg of surfactant were added and the suspension was gently stirred for 3 hours. The beads were filtered off with filter paper and the filtrate diluted to 15 mL with Milli-Q water and concentrated to 0.5 mL by ultrafiltration with Amicon Ultra-15
Centrifugal Filter Units (cut-off 10 kDa) at 4,000 g. The procedure (dilution-concentration) was repeated seven times. The resulting solution was diluted to the original volume and filtered through a 0.22 m cellulose acetate filter.
When required to prepare amine/OS/PEG nanoparticles, part of 1 was replaced with 2 (0.1 to 30 % in moles) to provide amine groups in the PEG. Some examples are given in the following table.
Note 1: The amino-PEG derivative 2, in DMSO solution, must be added to the reaction mixture just before the addition of ammonia.
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Folate and Biotin conjugated nanoparticles
To a preparation of crude (unpurified) amine/OS/PEG (as described in the previous paragraph)
Folate-OSu or Biotin-OSu dissolved in DMSO (20 equivalents with respect to the amount of 2 used in the synthesis of the nanoparticles) were added and the mixture was further stirred at 25 °C for 16
h. Then 14.3 mg of Bio-Beads  SM per mg of surfactant were added and the mixture was further gently stirred for 3 hours. The beads were filtered off with filter paper and the filtrate diluted to 15 mL with Milli-Q water and concentrated to 0.5 mL by ultrafiltration with Amicon Ultra-15
Centrifugal Filter Units (cut-off 10 kDa) at 4,000 g. The procedure was repeated seven times for biotin-conjugated nanoparticles and 10 times for folate-conjugate nanoparticles. The resulting solution was diluted to the original volume and filtered through a 0.22 m cellulose acetate filter.
RGD and RAD conjugated nanoparticles
Into a thermostated reaction vessel, PBS-10x (0.5 mL) was added to a purified preparation of amine/OS/PEG nanoparticles (5 mL). The pH was adjusted to 7.2, then MBS (20 equivalents with respect to the amount of 2 used for the synthesis of the nanoparticles) was added and the mixture was stirred at 30 °C for 16 h. The mixture was then filtered through a 0.45 m cellulose acetate filter, the filtrate was diluted to 15 mL with Milli-Q water and concentrated to 0.5 mL by ultrafiltration with an Amicon Ultra-15 Centrifugal Filter Unit (cut-off 10 kDa) at 4,000 g. The procedure was repeated seven times. The resulting solution was diluted to the original volume (5.5 mL) and filtered through a 0.22 m cellulose acetate membrane. HEPES buffer (5 mM, 0.5mL) was added and the pH was adjusted to 7. Then, the solution was split in three fractions of 2 mL each. (10 mM) buffer (pH 7.2) for 1 h at room temperature. Then, the resulting RGD/RAD solution (0.1 mL) was added to one of the nanoparticles aliquots (2 mL). The solutions were stirred overnight at RT. The solution was then diluted to 15 mL with Milli-Q water and concentrated to 0.5 mL by ultrafiltration with an Amicon Ultra-15 Centrifugal Filter Unit (cut-off 10 kDa) at 4,000 g. The procedure was repeated seven times. The resulting solution was diluted to the original volume and filtered through a 0.22 m cellulose acetate filter.
Cetuximab and Bovine Serum Albumin (BSA) conjugated nanoparticles
For the conjugation of these proteins to the nanoparticle surface we decided to derivatize the PEG-aminogroups with the cross-linker MBS using the same procedures described for the conjugation of RGD and RAD peptides, whereas the proteins (i.e.Cetuximab and BSA) were functionalized by 2-iminothiolane (2-IT) reaction that modified the NH2 of lysine introducing new free sulfhydryl groups. Briefly, the protein functionalization was performed o/n at 4°C, the reaction blocked with glycine 0.2 M for 20 minutes at r.t. and finally the derivatized proteins were purified by gel filtration on PD10 columns (Sephadex G-25M, GE Healthcare) in order to remove the excess of 2-IT. The number of introduced SH groups were calculated using the Ellman's assay; the NPprotein conjugation was performed o/n at 30°C and then a dialysis step was performed for 24hr at r.t. in PBS EDTA 10 mM.
At last nanoconjugates were purified from the unreacted reagent by a first step of centrifugation at 100,000 g for 45 minutes and a second step of size exclusion chromatography on HiLoad 16/60 column (Superdex 75 prep grade, GE Healthcare) using a FPLC apparatus (Biologic Workstation, Bio-Rad). The purified fractions were concentrated by centrifugation. Cetuximab-conjugated NPs (lane 1) and Cetuximab (lane 2) were separated by SDS-PAGE under non reducing condition and after the transfer onto a membrane of nitrocellulose the antibodies were stained using an anti-human antibody conjugated to HRP. Chemiluminescent signals, developed using ECL substrate, were detected by photographic films.
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Photophysical studies
Absorbance and Fluorescence Measurements
Absorbance spectra were measured using a Perkin-Elmer (Beaconsfield, UK) Lambda 25 UV/Vis spectrometer with 1 cm pathlength quartz cuvettes. Fluorescence spectra were measured using a Perkin-Elmer LS50-B spectrofluorimeter equipped with a bifurcated fiber-optic probe.
Fluorescence Lifetime Measurements
Fluorescence lifetimes were measured using time correlated single photon counting (TCSPC).
Dilute solutions were prepared with the dye concentration at 0.5 µM and placed in a 1 cm pathlength quartz cuvette. A pulsed laser diode module (90 picosecond pulse duration) was used to excite the samples at 405 nm at a 5MHz repetition rate (EPL-405, Edinburgh Instruments Ltd., UK). The fluorescence was detected using a fast multialkali photomultiplier module (model H5773-04, Hamamatusu Photonics K.K., Japan) via a longpass filter (OG510, Schott, UK) and a monochromator (model M300, Bentham Instrument Ltd, UK). A Lyot depolarizer (Thorlabs Ltd, UK) was incorporated to minimise any polarisation anisotropy artefacts. TCSPC was carried out using a PC-mounted TCSPC board (TimeHarp, Picoquant GmbH, Germany) and lifetimes were derived using Fluofit software (PicoQuant GmbH, Germany). The Instrument Response Function (IRF) was obtained from a non-fluorescent scattering Ludox® solution (Sigmal-Aldrich, Gillingham, UK). Optimum fitting with minimisation of the residuals was confirmed using a Chisquared value χ2< 1.4.
Singlet Oxygen Measurements
The singlet oxygen phosphorescence at 1270 nm was detected using time-resolved photon counting from air-equilibrated, deuterated aqueous or methanolic solutions in quartz cuvettes. For detection in the near-IR, a thermoelectrically cooled photomultiplier (model H10330-45, Hamamatsu
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Photonics Ltd, UK) was used, and emission was collected via a series of lenses from the cuvette in combination with a long-pass and a band-pass filter centered at 1270 nm (BK Interferenzoptik Electronik, Germany). The solutions were excited using a 532 mn Nd:YAG laser (Lumanova GmbH, Germany) with the beam axis aligned orthogonally to the collection optics. The laser was pulsed at a repetition rate of 3 kHz and a pulse length of 3 ns, giving a mean power of 8 mW, and a fast photodiode (1 ns rise time, Becker-Hickl, Berlin, Germany) was used to synchronise the laser pulse with the photon counting detection system. A series of neutral density filters was used to attenuate the laser power. The photon counting equipment consisted of a PC-mounted multiscaler board (model MSA-300, Becker-Hickl, Germany) and a pre-amplifier (Becker-Hickl, Germany)
which gave a resolution of 5 ns per channel. Time-resolved phosphorescence measurements were accumulated by the multiscaler board. The traces were analysed using FluoFit software (PicoQuant GmbH, Germany) to extract the singlet oxygen decay lifetime. To calculate the quantum yield, Rose Bengal was used as the standard which has singlet oxygen yields of 0.76 in D2O and 0.79 in MeOD (R. W. Redmond, and J. N. Gamlin, "A compilation of singlet oxygen yields from biologically relevant molecules" Photochem. Photobiol. 1999, 70, 391-475) . The concentrations were adjusted to give the same absorbance at 532 nm, and to analyse the time-resolved data we used the standard zero-intercept method.
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6. Protein binding studies
Nanoparticles incubation with human plasma
Venous blood was taken from healthy volunteers and immediately anticoagulated with 3.8% trisodium citrate (9 vol blood + 1 vol citrate). Plateled poor plasma (PPP) was obtained by centrifuging blood at 2,000 g for 10 min, without use of a brake. Plasma aliquots were frozen in liquid nitrogen and stored at -20°C until time of use. Before use, plasma was thawed and centrifuged at 16000 g at 4°C for 20 min, to eliminate any precipitate. Then, it was diluted in PBS EDTA 1 mM pH 7.4 at a final concentration of 24% (v/v), filtered through a 0.22 µM filter and incubated with PBS (ctrl) and 2 mg of Ormosil or Ludox nanoparticles for 1 hour at 37°C under gentle stirring. Then, nanoparticles were recovered by ultracentrifuging at 100,000 g for 1 h at 4°C, using a XL-70 Ultracentrifuge (Beckman), and washed twice with PBS EDTA 1 mM pH 7.4.
Identification of plasma proteins adsorbed to nanoparticles surface
The pellet of nanoparticles was dissolved in 150 µl of non-reducing sample buffer (50 mM Tris HCl pH 6.8, 2% SDS, 0.06% bromophenol blue, 6% glycerol) plus protease inhibitors cocktail (Sigma Aldrich), heated at 95°C for 5 min and loaded on a 12% (v/v) SDS-PAGE. After protein staining with colloidal Comassie G-250, bands of interest were excised and analyzed by mass spectrometry. In all the experiments, the cells (A549, CCD-34Lu, KB, A431, HeLa and HeLa EGFR +) were seeded and maintained for 24 h in culture medium supplemented with 10% FBS (complete medium) before starting the treatment; then, the medium was replaced with fresh medium containing 3% 
Measurement of EGFR down regulation induced by Cetuximab-conjugates NPs.
The day before the experiment 1x10 5 A431, HeLa and HeLa EGFR + cells were seeded on 24 wells plastic plates (Falcon). The day of the experiment, cells were incubated for two hours with different concentrations of Cetuximab or BSA-conjugated NPs (up to 50 μg/ml) at 37°C, then they were washed, trypsinized and stained with a FITC-conjugated anti-EGFR antibody (Abcam) for 30 minutes at 4°C. After washing, cells were analyzed by FACS, acquiring 10,000 events for each sample.
Confocal analysis of A431, HeLa and HeLa cells incubated with Cetuximab-conjugated
NPs. The day before the experiment, cells ( 1x10 5 ) were seeded on cover glasses; after 24 hours they were treated for two hours at 37°C with an amount of nanoparticles corresponding to 1 μM mTHPC, washed, fixed with 2% paraformaldehyde (Sigma) in PBS for 20 minutes at room temperature, permeabilized with 0.2% Triton X-100 (Sigma) for 10 minutes at 4°; cells were then washed and saturated with 1% BSA in PBS for 1 hour at room temperature; Cetuximab conjugated 
